1. The expression of tuftelin 1 as a new theranostic marker in early diagnosis and as a therapeutic target in hepatocellular carcinoma.
- Author
-
Abdel-Hamid NM, Zakaria SM, Ansary AM, El-Senduny FF, and El-Shishtawy MM
- Subjects
- Humans, Rats, Animals, Matrix Metalloproteinase 9 pharmacology, Vascular Endothelial Growth Factor A metabolism, Cyclin D1, Phosphatidylinositol 3-Kinases metabolism, Precision Medicine, Calcium, Proto-Oncogene Proteins c-akt metabolism, Early Diagnosis, Cell Proliferation, Cell Line, Tumor, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular metabolism, Liver Neoplasms diagnosis, Liver Neoplasms drug therapy, Liver Neoplasms metabolism
- Abstract
Currently, many challenges are associated with hepatocellular carcinoma (HCC) as the failure of early diagnosis, and the lack of effective therapy. This study aimed to investigate the possible role of tuftelin 1 (TUFT 1) in the early diagnosis of HCC and evaluate the potential contribution of the TUFT 1/Ca
+2 /phosphinositol 3 kinase (PI3K) pathway in dantrolene sodium (Dan) therapeutic outcomes. The study was performed on two sets of rats, the staging (30 rats) and treatment sets (80 rats). HCC was induced by a single dose of diethylnitrosamine (DENA). The hepatic content of TUFT 1 protein was assayed via western blot and immunohistochemistry (IHC), while PI3K, vascular endothelial growth factor (VEGF), Cyclin D1, and matrix-metalloproteinase-9 (MMP-9) contents were assessed using enzyme-linked immunosorbent assay. Hepatic and serum calcium were measured colorimetrically. Furthermore, the nuclear proliferation marker, (Ki-67), (Kiel [Ki] where the antibody was produced in the University Department of Pathology and the original clone number is 67)-expression was assessed by IHC. TUFT 1/Ca+2 /PI3K signaling pathway was progressively activated in the 3 studied stages of HCC with subsequent upregulation of angiogenesis, cell cycle, and metastasis. More interestingly, Dan led to TUFT 1/Ca+2 /PI3K pathway disruption by diminution of the hepatic contents of TUFT 1, calcium, PI3K, VEGF, Cyclin D1, and MMP-9 in a dose-dependent pattern. TUFT 1 can serve as a theranostic biomarker in HCC. Moreover, Dan exerted an antineoplastic effect against HCC via the interruption of TUFT 1/Ca+2 /PI3K pathway., (© 2023 John Wiley & Sons Ltd.)- Published
- 2023
- Full Text
- View/download PDF